Hepatitis Monthly

Published by: Kowsar

Effects of Green Coffee Bean Extract Supplementation on Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial

Hedayat Allah Shahmohammadi 1 , Seyed Ahmad Hosseini 1 , * , Eskandar Hajiani 2 , Amal Saki Malehi 3 and Meysam Alipour 1
Authors Information
1 Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Research Center for Infectious Diseases of the Digestive System, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
3 Health Research Institute, Thalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Hepatitis Monthly: April 2017, 17 (4); e12299
  • Published Online: March 26, 2017
  • Article Type: Research Article
  • Received: January 11, 2017
  • Revised: February 19, 2017
  • Accepted: March 8, 2017
  • DOI: 10.5812/hepatmon.45609

To Cite: Shahmohammadi H A, Hosseini S A, Hajiani E, Malehi A S, Alipour M. et al. Effects of Green Coffee Bean Extract Supplementation on Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial, Hepat Mon. 2017 ;17(4):e12299. doi: 10.5812/hepatmon.45609.

Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6): 1413-9[DOI][PubMed]
  • 2. Hu KC, Wang HY, Liu SC, Liu CC, Hung CL, Bair MJ, et al. Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol. 2014; 20(24): 7718-29[DOI][PubMed]
  • 3. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10(11): 686-90[DOI][PubMed]
  • 4. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990; 12(5): 1106-10[DOI][PubMed]
  • 5. Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med (Lond). 2006; 6(1): 19-25[PubMed]
  • 6. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10(6): 330-44[DOI][PubMed]
  • 7. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010; 52(1): 79-104[DOI][PubMed]
  • 8. Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des. 2013; 19(29): 5177-92[DOI][PubMed]
  • 9. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2): 372-84[DOI][PubMed]
  • 10. Del Ben M, Polimeni L, Baratta F, Pastori D, Angelico F. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br J Clin Pharmacol. 2017; 83(1): 88-95[DOI][PubMed]
  • 11. Esquivel P, Jiménez VM. Functional properties of coffee and coffee by-products. Food Res Int. 2012; 46(2): 488-95[DOI]
  • 12. van Dam RM. Coffee consumption and risk of type 2 diabetes, cardiovascular diseases, and cancer. Appl Physiol Nutr Metab. 2008; 33(6): 1269-83[DOI][PubMed]
  • 13. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord. 2007; 22(15): 2242-8[DOI][PubMed]
  • 14. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis. 2009; 16(1): 85-91[DOI][PubMed]
  • 15. Johnson S, Koh WP, Wang R, Govindarajan S, Yu MC, Yuan JM. Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Cancer Causes Control. 2011; 22(3): 503-10[DOI][PubMed]
  • 16. Yesil A, Yilmaz Y. Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013; 38(9): 1038-44[DOI][PubMed]
  • 17. Lecoultre V, Carrel G, Egli L, Binnert C, Boss A, MacMillan EL, et al. Coffee consumption attenuates short-term fructose-induced liver insulin resistance in healthy men. Am J Clin Nutr. 2014; 99(2): 268-75[DOI][PubMed]
  • 18. Gupta V, Mah XJ, Garcia MC, Antonypillai C, van der Poorten D. Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease. World J Gastroenterol. 2015; 21(37): 10621-35[DOI][PubMed]
  • 19. Godos J, Pluchinotta FR, Marventano S, Buscemi S, Li Volti G, Galvano F, et al. Coffee components and cardiovascular risk: beneficial and detrimental effects. Int J Food Sci Nutr. 2014; 65(8): 925-36[DOI][PubMed]
  • 20. H VS, K V, Patel D, K S. Biomechanism of chlorogenic acid complex mediated plasma free fatty acid metabolism in rat liver. BMC Complement Altern Med. 2016; 16: 274[DOI][PubMed]
  • 21. Sarriá B, Martínez-López S, Mateos R, Bravo-Clemente L. Long-term consumption of a green/roasted coffee blend positively affects glucose metabolism and insulin resistance in humans. Food Res Int. 2016; 89: 1023-8[DOI]
  • 22. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002; 137(1): 1-10[DOI][PubMed]
  • 23. Vinson JA, Burnham BR, Nagendran MV. Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects. Diabetes Metab Syndr Obes. 2012; 5: 21-7[DOI][PubMed]
  • 24. Thom E. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people. J Int Med Res. 2007; 35(6): 900-8[DOI][PubMed]
  • 25. Health NIO, Obesity Education Initiative NHLBI, Association for the Study of Obesity NA. The practical guide: Identification, evaluation, and treatment of overweight and obesity in adults. 2000;
  • 26. Stohs SJ, Badmaev V. A review of natural stimulant and non-stimulant thermogenic agents. Phytother Res. 2016; 30(5): 732-40[DOI]
  • 27. Onakpoya I, Terry R, Ernst E. The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. Gastroenterol Res Pract. 2011; 2011[DOI][PubMed]
  • 28. Flanagan J, Bily A, Rolland Y, Roller M. Lipolytic activity of Svetol(R), a decaffeinated green coffee bean extract. Phytother Res. 2014; 28(6): 946-8[DOI][PubMed]
  • 29. Narita Y, Iwai K, Fukunaga T, Nakagiri O. Inhibitory activity of chlorogenic acids in decaffeinated green coffee beans against porcine pancreas lipase and effect of a decaffeinated green coffee bean extract on an emulsion of olive oil. Biosci Biotechnol Biochem. 2012; 76(12): 2329-31[DOI][PubMed]
  • 30. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013; 5(5): 1544-60[DOI][PubMed]
  • 31. Chen Y, Varghese Z, Ruan XZ. The molecular pathogenic role of inflammatory stress in dysregulation of lipid homeostasis and hepatic steatosis. Genes Dis. 2014; 1(1): 106-12[DOI]
  • 32. Yukawa GS, Mune M, Otani H, Tone Y, Liang XM, Iwahashi H, et al. Effects of coffee consumption on oxidative susceptibility of low-density lipoproteins and serum lipid levels in humans. Biochemistry (Mosc). 2004; 69(1): 70-4[DOI][PubMed]
  • 33. Rodriguez de Sotillo DV, Hadley M. Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J Nutr Biochem. 2002; 13(12): 717-26[DOI][PubMed]
  • 34. Ong KW, Hsu A, Tan BK. Anti-diabetic and anti-lipidemic effects of chlorogenic acid are mediated by ampk activation. Biochem Pharmacol. 2013; 85(9): 1341-51[DOI][PubMed]
  • 35. Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008; 28(2): 200-8[DOI][PubMed]
  • 36. Salgado AL, Carvalho L, Oliveira AC, Santos VN, Vieira JG, Parise ER. Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol. 2010; 47(2): 165-9[DOI][PubMed]
  • 37. Kempf K, Herder C, Erlund I, Kolb H, Martin S, Carstensen M, et al. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr. 2010; 91(4): 950-7[DOI][PubMed]
  • 38. Ohnaka K, Ikeda M, Maki T, Okada T, Shimazoe T, Adachi M, et al. Effects of 16-week consumption of caffeinated and decaffeinated instant coffee on glucose metabolism in a randomized controlled trial. J Nutr Metab. 2012; 2012: 207426[DOI][PubMed]
  • 39. Wedick NM, Brennan AM, Sun Q, Hu FB, Mantzoros CS, van Dam RM. Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. Nutr J. 2011; 10: 93[DOI][PubMed]
  • 40. Pham NM, Nanri A, Kochi T, Kuwahara K, Tsuruoka H, Kurotani K, et al. Coffee and green tea consumption is associated with insulin resistance in Japanese adults. Metabolism. 2014; 63(3): 400-8[DOI][PubMed]
  • 41. McAnlis GT, McEneny J, Pearce J, Young IS. Black tea consumption does not protect low density lipoprotein from oxidative modification. Eur J Clin Nutr. 1998; 52(3): 202-6[DOI][PubMed]
  • 42. Mechanisms of disease progression in nonalcoholic fatty liver disease. Seminars in liver disease.
  • 43. Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006; 44(6): 1167-74[DOI][PubMed]
  • 44. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355(22): 2297-307[DOI][PubMed]
  • 45. Maki T, Pham NM, Yoshida D, Yin G, Ohnaka K, Takayanagi R, et al. The relationship of coffee and green tea consumption with high-sensitivity C-reactive protein in Japanese men and women. Clin Chem Lab Med. 2010; 48(6): 849-54[DOI][PubMed]
  • 46. Vitaglione P, Morisco F, Mazzone G, Amoruso DC, Ribecco MT, Romano A, et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology. 2010; 52(5): 1652-61[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader